De-risk therapy development
Enable reproducible histologic assessment across timepoints and patients; histology compliments traditional measures of disease activity and reliable assessment can help complete understanding of drug outcomes
Simplify complex workflows
Bridge multiple scoring systems (Geboes subgrades, Robarts Histopathology Index, and Nancy Histological Index) instantaneously to adapt to evolving UC regulatory guidance
Robust development
Trained and evaluated on a vast and diverse dataset of >9,000 biopsies from across six different clinical trials and clinical sources with median consensus scores from three GI pathologists
Specifications
- Indication: Ulcerative Colitis
- Intended Use: Research Use Only. Not for use in diagnostic procedures; for use as an AI-assisted secondary and/or exploratory endpoint in clinical trials to identify histologic remission (GS<2A.0 or 2B.0) and histologic improvement (GS≤3.1).
- Assay: H&E sigmoid and rectum biopsies
- Scanner: Leica Aperio® AT2 and GT450
- Outputs: Pathologist AI-assisted Geboes subgrades and Nancy Histological Index; extracted Geboes Grade Level Score, calculated Robarts Histopathology Index
Automated and reproducible scoring across all indices
AIM-HI UC outputs include all Geboes subgrades, extracted Geboes Grade Level Score, calculated Robarts Histopathology Index, converted Nancy Histological Index, Histologic Improvement and Histologic Remission Detection.
.jpg)